Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China.
China
EQ-5D-5L
Health-related quality of life (HRQOL)
Influencing factors
Paroxysmal nocturnal hemoglobinuria
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
received:
01
01
2024
accepted:
30
03
2024
medline:
4
5
2024
pubmed:
4
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder, leading to various complications and impairments in patients' health-related quality of life (HRQOL). Limited research has been conducted to evaluate the HRQOL of Chinese patients with PNH. Understanding the HRQOL in this specific population is crucial for providing effective healthcare interventions and improving patient' health outcomes. This study aimed to assess HRQOL of Chinese patients with PNH, and identify key determinants. A cross-sectional study was conducted during 2022 to recruit patients with PNH in China. The study population was recruited from PNH China, one of the largest public welfare PNH patient mutual aid organization in China. Data were collected via an online questionnaire including the EQ-5D-5L (5L), and social-demographic and clinical characteristics. Descriptive statistics were employed to summarize the characteristics of the participants and their HRQOL. Multiple linear and logistic regression analyses were adopted to explore key factors affecting HRQOL. A total of 329 valid questionnaires were collected. The mean (SD) age of the patients was 35.3 (10.0) years, with 52.3% of them being male. The patients reported more problems in Anxiety/Depression (81.5%) and Pain/Discomfort (69.9%) dimensions compared to the other three 5L dimensions. The mean (SD) of 5L health utility score (HUS) and EQ-VAS score were 0.76 (0.21) and 62.61 (19.20), respectively. According to multiple linear regression, initial symptoms (i.e., Anemia [fatigue, tachycardia, shortness of breath, headache] and back pain) and complication of thrombosis were significant influencing factors affecting 5L HUS. Total personal income of the past year, initial symptom of hemoglobinuria and complication of thrombosis were significantly influencing factors of VAS score. Social-demographic and clinical characteristics, such as gender, income, and thrombosis, were also found to be significantly related to certain 5L health problems as well. Our study manifested the HRQOL of PNH patients in China was markedly compromised, especially in two mental-health related dimensions, and revealed several socio-demographic and clinical factors of their HRQOL. These findings could be used as empirical evidence for enhancing the HRQOL of PNH patients in China.
Sections du résumé
BACKGROUND
BACKGROUND
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder, leading to various complications and impairments in patients' health-related quality of life (HRQOL). Limited research has been conducted to evaluate the HRQOL of Chinese patients with PNH. Understanding the HRQOL in this specific population is crucial for providing effective healthcare interventions and improving patient' health outcomes. This study aimed to assess HRQOL of Chinese patients with PNH, and identify key determinants.
METHODS
METHODS
A cross-sectional study was conducted during 2022 to recruit patients with PNH in China. The study population was recruited from PNH China, one of the largest public welfare PNH patient mutual aid organization in China. Data were collected via an online questionnaire including the EQ-5D-5L (5L), and social-demographic and clinical characteristics. Descriptive statistics were employed to summarize the characteristics of the participants and their HRQOL. Multiple linear and logistic regression analyses were adopted to explore key factors affecting HRQOL.
RESULTS
RESULTS
A total of 329 valid questionnaires were collected. The mean (SD) age of the patients was 35.3 (10.0) years, with 52.3% of them being male. The patients reported more problems in Anxiety/Depression (81.5%) and Pain/Discomfort (69.9%) dimensions compared to the other three 5L dimensions. The mean (SD) of 5L health utility score (HUS) and EQ-VAS score were 0.76 (0.21) and 62.61 (19.20), respectively. According to multiple linear regression, initial symptoms (i.e., Anemia [fatigue, tachycardia, shortness of breath, headache] and back pain) and complication of thrombosis were significant influencing factors affecting 5L HUS. Total personal income of the past year, initial symptom of hemoglobinuria and complication of thrombosis were significantly influencing factors of VAS score. Social-demographic and clinical characteristics, such as gender, income, and thrombosis, were also found to be significantly related to certain 5L health problems as well.
CONCLUSION
CONCLUSIONS
Our study manifested the HRQOL of PNH patients in China was markedly compromised, especially in two mental-health related dimensions, and revealed several socio-demographic and clinical factors of their HRQOL. These findings could be used as empirical evidence for enhancing the HRQOL of PNH patients in China.
Identifiants
pubmed: 38702811
doi: 10.1186/s13023-024-03178-x
pii: 10.1186/s13023-024-03178-x
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Subventions
Organisme : Dalian Medical University Maternal Diseases on Newborns Interdisciplinary Research Cooperation Project Team Funding
ID : JCHZ2023016
Organisme : A Real World Study on the Situation of Children's Medical Security in Liaoning Province Based on Interrupted Time Series Analysis
ID : LJKMR20221296
Informations de copyright
© 2024. The Author(s).
Références
Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–11. https://doi.org/10.1182/blood-2014-02-522128 .
doi: 10.1182/blood-2014-02-522128
pubmed: 25237200
pmcid: 4215311
Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https://doi.org/10.1038/nrdp.2017.28 . Published 2017 May 18.
doi: 10.1038/nrdp.2017.28
pubmed: 28516949
pmcid: 7879566
Panse J. Paroxysmal nocturnal hemoglobinuria: where we stand. Am J Hematol. 2023;98(Suppl 4):S20–32. https://doi.org/10.1002/ajh.26832 .
doi: 10.1002/ajh.26832
pubmed: 36594182
Szlendak U, Budziszewska B, Spychalska J, et al. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med. 2022;132(6):16271. https://doi.org/10.20452/pamw.16271 .
doi: 10.20452/pamw.16271
pubmed: 35699625
Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341–8. https://doi.org/10.1016/j.htct.2020.06.006 .
doi: 10.1016/j.htct.2020.06.006
pubmed: 32713742
Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8. https://doi.org/10.1056/NEJM199511093331904 .
doi: 10.1056/NEJM199511093331904
pubmed: 7566002
Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728. https://doi.org/10.1177/2040620719874728 . Published 2019 Sep 10.
doi: 10.1177/2040620719874728
pubmed: 31534662
pmcid: 6737867
Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699–709. https://doi.org/10.1182/blood-2005-04-1717 .
doi: 10.1182/blood-2005-04-1717
pubmed: 16051736
pmcid: 1895106
Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J. 2016;46(9):1044–53. https://doi.org/10.1111/imj.13160 .
doi: 10.1111/imj.13160
pubmed: 27305361
Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103(6):649–54. https://doi.org/10.1007/s12185-016-1995-1 .
doi: 10.1007/s12185-016-1995-1
pubmed: 27059871
Muñoz-Linares C, Ojeda E, Forés R, et al. Paroxysmal nocturnal hemoglobinuria: a single Spanish center’s experience over the last 40 year. Eur J Haematol. 2014;93(4):309–19. https://doi.org/10.1111/ejh.12346 .
doi: 10.1111/ejh.12346
pubmed: 24758317
pmcid: 4232878
Guidelines for Diagnosis and Treatment of Rare Diseases in China. 2019;547–554.
Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922–9. https://doi.org/10.3324/haematol.2013.093161 .
doi: 10.3324/haematol.2013.093161
pubmed: 24488565
pmcid: 4008114
Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505–14. https://doi.org/10.1007/s00277-020-04052-z .
doi: 10.1007/s00277-020-04052-z
pubmed: 32390114
pmcid: 7316848
Gao Z, Wang P, Hong J et al. Health-related quality of life among Chinese patients with Crohn’s disease: a cross-sectional survey using the EQ-5D-5L. Health Qual Life Outcomes. 2022;20(1):62. Published 2022 Apr 12. https://doi.org/10.1186/s12955-022-01969-z .
Karimi M, Brazier J. Health, Health-Related Quality of Life, and quality of life: what is the difference? PharmacoEconomics. 2016;34:645–9. https://doi.org/10.1007/s40273-016-0389-9 .
doi: 10.1007/s40273-016-0389-9
pubmed: 26892973
Yin S, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model. Popul Health Metrics. 2016;14:22. https://doi.org/10.1186/s12963-016-0091-3 .
doi: 10.1186/s12963-016-0091-3
Young NS, Meyers G, Schrezenmeier H, et al. The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl 1):S1–16. https://doi.org/10.1053/j.seminhematol.2008.11.004 .
doi: 10.1053/j.seminhematol.2008.11.004
pubmed: 19171207
pmcid: 3402209
Panse J, Sicre de Fontbrune F, Burmester P, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. Eur J Haematol. 2022;109(4):351–63. https://doi.org/10.1111/ejh.13816 .
doi: 10.1111/ejh.13816
pubmed: 35746830
pmcid: 9545353
Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE. 2020;15(9):e0237497. https://doi.org/10.1371/journal.pone.0237497 . Published 2020 Sep 4.
doi: 10.1371/journal.pone.0237497
pubmed: 32886668
pmcid: 7473546
Desai D, Hadker N, Francis A, et al. Health-Related Quality of Life reported among patients with Paroxysmal Nocturnal Hemoglobinuria: impact of treatment with Pegcetacoplan and C5-Inhibitors. Blood. 2022;140:11445–46. https://doi.org/10.1182/blood-2022-163821 .
doi: 10.1182/blood-2022-163821
Quist SW, Postma AJ, Myrén KJ, et al. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands. Eur J Health Econ. 2023;24(9):1455–72. https://doi.org/10.1007/s10198-022-01556-5 .
doi: 10.1007/s10198-022-01556-5
pubmed: 36633725
pmcid: 10550878
Zhou T, Guan H, Wang L, et al. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review. Front Public Health. 2021;9:675523. https://doi.org/10.3389/fpubh.2021.675523 . Published 2021 Jun 29.
doi: 10.3389/fpubh.2021.675523
pubmed: 34268287
pmcid: 8275935
Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. PharmacoEconomics. 2020;38(6):575–91. https://doi.org/10.1007/s40273-020-00893-8 .
doi: 10.1007/s40273-020-00893-8
pubmed: 32180162
Christiansen ASJ, Møller MLS, Kronborg C, et al. Comparison of the three-level and the five-level versions of the EQ-5D. Eur J Health Econ. 2021;22(4):621–8. https://doi.org/10.1007/s10198-021-01279-z .
doi: 10.1007/s10198-021-01279-z
pubmed: 33733344
Pan CW, He JY, Zhu YB, et al. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients. Eur J Health Econ. 2023;24(6):885–93. https://doi.org/10.1007/s10198-022-01523-0 .
doi: 10.1007/s10198-022-01523-0
pubmed: 36083356
Pan CW, Ma Q, Sun HP, et al. Tea consumption and health-related quality of life in older adults. J Nutr Health Aging. 2017;21(5):480–6. https://doi.org/10.1007/s12603-016-0784-0 .
doi: 10.1007/s12603-016-0784-0
pubmed: 28448076
Luo N, Liu G, Li M, et al. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662–9. https://doi.org/10.1016/j.jval.2016.11.016 .
doi: 10.1016/j.jval.2016.11.016
pubmed: 28408009
Statistical Bulletin of the People’s Republic of China on National Economic and Social Development in 2021. China Stat. 2022;(03):9–26.
Moyo VM, Mukhina GL, Garrett ES, et al. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126(1):133–8. https://doi.org/10.1111/j.1365-2141.2004.04992.x .
doi: 10.1111/j.1365-2141.2004.04992.x
pubmed: 15198744
Ge M, Li X, Shi J, et al. Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Ann Hematol. 2012;91(7):1121–8. https://doi.org/10.1007/s00277-012-1413-6 .
doi: 10.1007/s00277-012-1413-6
pubmed: 22281992
Fu R, Li L, Li L, et al. Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: a single institution experience in China. J Clin Lab Anal. 2020;34(1):e23008. https://doi.org/10.1002/jcla.23008 .
doi: 10.1002/jcla.23008
pubmed: 31502726
Cheng WY, Sarda SP, Mody-Patel N, et al. Real-world Healthcare Resource utilization (HRU) and costs of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) receiving Eculizumab in a US Population. Adv Ther. 2021;38(8):4461–79. https://doi.org/10.1007/s12325-021-01825-4 .
doi: 10.1007/s12325-021-01825-4
pubmed: 34275086
pmcid: 8342328
Bektas M, Copley-Merriman C, Khan S, et al. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020;26(12–b Suppl):S14–20. https://doi.org/10.18553/jmcp.2020.26.12-b.s14 .
doi: 10.18553/jmcp.2020.26.12-b.s14
pubmed: 33356783
Bektas M, Copley-Merriman C, Khan S, et al. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12–b Suppl):S8–14. https://doi.org/10.18553/jmcp.2020.26.12-b.s8 .
doi: 10.18553/jmcp.2020.26.12-b.s8
pubmed: 33356781
Jang JH, Kim JS, Yoon SS, et al. Predictive factors of Mortality in Population of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016;31(2):214–21. https://doi.org/10.3346/jkms.2016.31.2.214 .
doi: 10.3346/jkms.2016.31.2.214
pubmed: 26839475
pmcid: 4729501
Röth A, Maciejewski J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018;101(1):3–11. https://doi.org/10.1111/ejh.13059 .
doi: 10.1111/ejh.13059
pubmed: 29532535
Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304–9. https://doi.org/10.1182/blood.2019003812 .
doi: 10.1182/blood.2019003812
pubmed: 33512400
pmcid: 7955407
de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106. https://doi.org/10.1182/blood-2008-01-133918 .
doi: 10.1182/blood-2008-01-133918
pubmed: 18535202
Lee JW, Jang JH, Lee JH, HIGH PREVALENCE AND MORTALITY ASSOCIATED WITH THROMBOEMBOLISM IN ASIAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), et al. HAEMATOLOGICA-THE Hematol J. 2010;95:205–06.
Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97(6):749–57. https://doi.org/10.1007/s12185-013-1346-4 .
doi: 10.1007/s12185-013-1346-4
pubmed: 23636668
Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009;113(26):6522–7. https://doi.org/10.1182/blood-2009-03-195966 .
doi: 10.1182/blood-2009-03-195966
pubmed: 19372253
pmcid: 2710914
Luzzatto L. PNH phenotypes and their genesis. Br J Haematol. 2020;189(5):802–5. https://doi.org/10.1111/bjh.16473 .
doi: 10.1111/bjh.16473
pubmed: 32166737
Gulbis B, Eleftheriou A, Angastiniotis M, et al. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375–96. https://doi.org/10.1007/978-90-481-9485-8_22 .
doi: 10.1007/978-90-481-9485-8_22
pubmed: 20824457
Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149(3):414–25. https://doi.org/10.1111/j.1365-2141.2010.08096.x .
doi: 10.1111/j.1365-2141.2010.08096.x
pubmed: 20230403
Yenerel MN, Muus P, Wilson A, et al. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. Blood Cells Mol Dis. 2017;65:29–34. https://doi.org/10.1016/j.bcmd.2017.03.013 .
doi: 10.1016/j.bcmd.2017.03.013
pubmed: 28437723
Waheed A, Kaufhold S, Liu C-R, et al. A systematic literature review of clinical and economic outcomes for patients with paroxysmal nocturnal hemoglobinuria in clinical trials and real-world settings. Blood. 2022;140:11451–52. https://doi.org/10.1182/blood-2022-167531 .
doi: 10.1182/blood-2022-167531
Cella D, Sarda SP, Hsieh R, et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol. 2022;101(9):1905–14. https://doi.org/10.1007/s00277-022-04887-8 .
doi: 10.1007/s00277-022-04887-8
pubmed: 35869984
pmcid: 9375756
Chatzileontiadou S, Hatjiharissi E, Angelopoulou M, et al. Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): real world data of a Greek nationwide multicenter retrospective study. Front Oncol. 2023;13:1128994. https://doi.org/10.3389/fonc.2023.1128994 . Published 2023 Mar 7.
doi: 10.3389/fonc.2023.1128994
pubmed: 36959785
pmcid: 10028290
Zhang TQ, Wu HY, Cai YF, et al. Researches on the Status of Life Quality of Chinese Population and its influencing factors based on EQ-5D-5L and SF-6D scales. Chin Health Service Manage. 2020;8(08):631–4.
Fattizzo B, Cavallaro F, Oliva EN, et al. Managing fatigue in patients with Paroxysmal Nocturnal Hemoglobinuria: a patient-focused perspective. J Blood Med. 2022;13:327–35. https://doi.org/10.2147/JBM.S339660 . Published 2022 Jun 17.
doi: 10.2147/JBM.S339660
pubmed: 35747742
pmcid: 9211741
Norström F, Virtanen P, Hammarström A, et al. How does unemployment affect self-assessed health? A systematic review focusing on subgroup effects. BMC Public Health. 2014;14:1310. https://doi.org/10.1186/1471-2458-14-1310 . Published 2014 Dec 22.
doi: 10.1186/1471-2458-14-1310
pubmed: 25535401
pmcid: 4364585
Thornton RL, Glover CM, Cené CW, et al. Evaluating strategies for reducing Health disparities by addressing the Social Determinants of Health. Health Aff (Millwood). 2016;35(8):1416–23. https://doi.org/10.1377/hlthaff.2015.1357 .
doi: 10.1377/hlthaff.2015.1357
pubmed: 27503966
Braveman P, Egerter S, Williams DR. The social determinants of health: coming of age. Annu Rev Public Health. 2011;32:381–98. https://doi.org/10.1146/annurev-publhealth-031210-101218 .
doi: 10.1146/annurev-publhealth-031210-101218
pubmed: 21091195
Kim S, Love F, Quistberg DA, et al. Association of health literacy with self-management behavior in patients with diabetes. Diabetes Care. 2004;27(12):2980–2. https://doi.org/10.2337/diacare.27.12.2980 .
doi: 10.2337/diacare.27.12.2980
pubmed: 15562219
Rani PK, Raman R, Subramani S, et al. Knowledge of diabetes and diabetic retinopathy among rural populations in India, and the influence of knowledge of diabetic retinopathy on attitude and practice. Rural Remote Health. 2008;8(3):838.
pubmed: 18656993
Lemes Dos Santos PF, Dos Santos PR, Ferrari GS, et al. Knowledge of diabetes mellitus: does gender make a difference? Osong Public Health Res Perspect. 2014;5(4):199–203. https://doi.org/10.1016/j.phrp.2014.06.004 .
doi: 10.1016/j.phrp.2014.06.004
pubmed: 25379370
pmcid: 4215000
Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653–62. https://doi.org/10.1001/jama.293.13.1653 .
doi: 10.1001/jama.293.13.1653
pubmed: 15811985
Weitz I, Meyers G, Lamy T, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013;43(3):298–307. https://doi.org/10.1111/j.1445-5994.2012.02924.x .
doi: 10.1111/j.1445-5994.2012.02924.x
pubmed: 22909078
Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190(S7):S54–60. https://doi.org/10.5694/j.1326-5377.2009.tb02471.x .
doi: 10.5694/j.1326-5377.2009.tb02471.x
pubmed: 19351294
Lamé IE, Peters ML, Vlaeyen JW, et al. Quality of life in chronic pain is more associated with beliefs about pain, than with pain intensity. Eur J Pain. 2005;9(1):15–24. https://doi.org/10.1016/j.ejpain.2004.02.006 .
doi: 10.1016/j.ejpain.2004.02.006
pubmed: 15629870
Escalante CP, Chisolm S, Song J, et al. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Med. 2019;8(2):543–53. https://doi.org/10.1002/cam4.1953 .
doi: 10.1002/cam4.1953
pubmed: 30632713
pmcid: 6382725